UK markets close in 59 minutes

AgeX Therapeutics, Inc. (AGE)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
0.6828-0.0472 (-6.47%)
As of 10:27AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.7300
Open0.7100
Bid0.7100 x 3000
Ask0.7650 x 900
Day's range0.6828 - 0.7375
52-week range0.5160 - 1.7700
Volume17,186
Avg. volume54,957
Market cap27.363M
Beta (5Y monthly)1.39
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors

    ALAMEDA, Calif., May 18, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that Dr. Joanne Hackett has been appointed Chairperson of AgeX’s Board of Directors. Dr. Hackett joined the Board of Directors in December 2021. She will serve in a non-executive capacity as AgeX’s Chairperson. Dr. Greg Bailey, who served as AgeX’s Chairperson since 2018, will continue to serve as a member of AgeX’s

  • Business Wire

    AgeX Therapeutics Reports First Quarter 2022 Financial Results

    ALAMEDA, Calif., May 13, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2022.

  • Business Wire

    AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results

    ALAMEDA, Calif., March 29, 2022--AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for fourth quarter and the full year ended December 31, 2021.